Mometasone/nortriptyline

Drug Profile

Mometasone/nortriptyline

Alternative Names: CRx-191; Nortriptyline/mometasone

Latest Information Update: 29 Mar 2011

Price : $50

At a glance

  • Originator CombinatoRx
  • Developer Zalicus
  • Class Anti-inflammatories; Dibenzocycloheptenes; Glucocorticoids; Pregnadienediols
  • Mechanism of Action Lipocortin synthesis agonists; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-II for Psoriasis in Germany (Topical)
  • 09 Sep 2010 CombinatoRx is now called Zalicus
  • 13 Mar 2008 Interim efficacy and adverse event data from a phase II trial in psorasis released by CombinatoRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top